Literature DB >> 20299600

Novel anti-inflammatory functions for endothelial and myeloid cyclooxygenase-2 in a new mouse model of Crohn's disease.

Junji Watanabe1, James A Lin, Ajay J Narasimha, Ani Shahbazian, Tomo-O Ishikawa, Martin G Martin, Harvey R Herschman, Srinivasa T Reddy.   

Abstract

Cyclooxygenase-2 (COX-2) is an important regulator of inflammation implicated in the development of a variety of diseases, including inflammatory bowel disease (IBD). However, the regulation of intestinal inflammation by COX-2 is poorly understood. We previously reported that COX-2(-/-) mice fed a cholate-containing high-fat (CCHF) diet had high mortality of unknown mechanisms attributable to severe intestinal inflammation in the ileo-ceco-colic junction that presented characteristics similar to Crohn's disease (CD). To further characterize the role of COX-2 in intestinal inflammation, we established cell-specific conditional COX-2(-/-) mice. Endothelial cell-specific (COX-2(-E/-E)) and myeloid cell-specific (COX-2(-M/-M)) COX-2(-/-) mice, but not wild-type mice, on the CCHF diet developed localized CD-like pathology at the ileo-ceco-colic junction that was associated with cellular infiltration, increased expression of myeloperoxidase and IL-5, and decreased IL-10 expression. The CD-like pathology in COX-2(-E/-E) mice was also accompanied by increased expression of cytokines (IL-6, TNF-alpha, and INF-gamma), compared with wild-type mice and COX-2(-M/-M) mice. In contrast, the ileo-ceco-colic inflammation in COX-2(-M/-M) mice was associated with more pronounced infiltration of granulocytes and macrophages than COX-2(-E/-E) mice. COX-2(-ME/-ME) (COX-2(-M/-M) x COX-2(-E/-E)) mice on the CCHF diet developed CD-like pathology in the ileo-ceco-colic junction reminiscent of total COX-2(-/-) mice on CCHF diet and wild-type mice on CCHF diet treated with COX-2 inhibitor, celecoxib. The pathology of diet-mediated ileo-ceco-colic inflammation in COX-2(-/-) mice offers an excellent model system to elucidate the protective roles of endothelial and myeloid COX-2 and the molecular pathogenesis of CD.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20299600      PMCID: PMC8875131          DOI: 10.1152/ajpgi.00468.2009

Source DB:  PubMed          Journal:  Am J Physiol Gastrointest Liver Physiol        ISSN: 0193-1857            Impact factor:   4.052


  57 in total

1.  Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids.

Authors:  F Catella-Lawson; B McAdam; B W Morrison; S Kapoor; D Kujubu; L Antes; K C Lasseter; H Quan; B J Gertz; G A FitzGerald
Journal:  J Pharmacol Exp Ther       Date:  1999-05       Impact factor: 4.030

2.  Crohn's disease and IL-10 therapy: promise regained.

Authors:  Willem J S de Villiers
Journal:  Inflamm Bowel Dis       Date:  2003-05       Impact factor: 5.325

Review 3.  Nonsteroidal anti-inflammatory drugs and inflammatory bowel disease: current perspectives.

Authors:  Giovanna Cipolla; Francesca Crema; Stefano Sacco; Elisabetta Moro; Fabrizio de Ponti; Gianmario Frigo
Journal:  Pharmacol Res       Date:  2002-07       Impact factor: 7.658

4.  Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial.

Authors:  Michael E Farkouh; Howard Kirshner; Robert A Harrington; Sean Ruland; Freek W A Verheugt; Thomas J Schnitzer; Gerd R Burmester; Eduardo Mysler; Marc C Hochberg; Michael Doherty; Elena Ehrsam; Xavier Gitton; Gerhard Krammer; Bernhard Mellein; Alberto Gimona; Patrice Matchaba; Christopher J Hawkey; James H Chesebro
Journal:  Lancet       Date:  2004 Aug 21-27       Impact factor: 79.321

5.  Cyclooxygenase-2-dependent arachidonic acid metabolites are essential modulators of the intestinal immune response to dietary antigen.

Authors:  R D Newberry; W F Stenson; R G Lorenz
Journal:  Nat Med       Date:  1999-08       Impact factor: 53.440

6.  Development and validation of a novel IL-10 deficient cell transfer model for colitis.

Authors:  Yuka Ikenoue; Tomoyuki Tagami; Masahiro Murata
Journal:  Int Immunopharmacol       Date:  2005-06       Impact factor: 4.932

7.  Differential inhibition of human prostaglandin endoperoxide synthase-1 and -2 by nonsteroidal anti-inflammatory drugs.

Authors:  P Patrignani; M R Panara; M G Sciulli; G Santini; G Renda; C Patrono
Journal:  J Physiol Pharmacol       Date:  1997-12       Impact factor: 3.011

8.  Atherogenic diet causes lethal ileo-ceco-colitis in cyclooxygenase-2 deficient mice.

Authors:  James A Lin; Junji Watanabe; Nora Rozengurt; Ajay Narasimha; Martin G Martin; Jenny Wang; Jonathan Braun; Robert Langenbach; Srinivasa T Reddy
Journal:  Prostaglandins Other Lipid Mediat       Date:  2007-04-25       Impact factor: 3.072

9.  Phagocytotic activation of muscularis resident macrophages inhibits smooth muscle contraction in rat ileum.

Authors:  Koichi Sato; Shigeko Torihashi; Masatoshi Hori; Tetsuyuki Nasu; Hiroshi Ozaki
Journal:  J Vet Med Sci       Date:  2007-10       Impact factor: 1.267

10.  Isolation and subsequent analysis of murine lamina propria mononuclear cells from colonic tissue.

Authors:  Benno Weigmann; Ingrid Tubbe; Daniel Seidel; Alex Nicolaev; Christoph Becker; Markus F Neurath
Journal:  Nat Protoc       Date:  2007       Impact factor: 13.491

View more
  5 in total

1.  Intracellular pathogen sensor NOD2 programs macrophages to trigger Notch1 activation.

Authors:  Kushagra Bansal; Kithiganahalli N Balaji
Journal:  J Biol Chem       Date:  2010-12-14       Impact factor: 5.157

Review 2.  High-density lipoprotein and 4F peptide reduce systemic inflammation by modulating intestinal oxidized lipid metabolism: novel hypotheses and review of literature.

Authors:  Mohamad Navab; Srinivasa T Reddy; Brian J Van Lenten; Georgette M Buga; Greg Hough; Alan C Wagner; Alan M Fogelman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-11       Impact factor: 8.311

Review 3.  Mucosal macrophages in intestinal homeostasis and inflammation.

Authors:  Allan McI Mowat; Calum C Bain
Journal:  J Innate Immun       Date:  2011-09-19       Impact factor: 7.349

4.  Apolipoprotein A-I mimetics mitigate intestinal inflammation in COX2-dependent inflammatory bowel disease model.

Authors:  David Meriwether; Dawoud Sulaiman; Carmen Volpe; Anna Dorfman; Victor Grijalva; Nasrin Dorreh; R Sergio Solorzano-Vargas; Jifang Wang; Ellen O'Connor; Jeremy Papesh; Muriel Larauche; Hannah Trost; Mayakonda N Palgunachari; G M Anantharamaiah; Harvey R Herschman; Martin G Martin; Alan M Fogelman; Srinivasa T Reddy
Journal:  J Clin Invest       Date:  2019-06-11       Impact factor: 19.456

5.  Regulation of Intestinal Inflammation by Dietary Fats.

Authors:  Abigail R Basson; Christy Chen; Filip Sagl; Ashley Trotter; Ilya Bederman; Adrian Gomez-Nguyen; Mark S Sundrud; Sanja Ilic; Fabio Cominelli; Alex Rodriguez-Palacios
Journal:  Front Immunol       Date:  2021-02-02       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.